LIPELLA PHARMACEUTICALS INC (LIPO) Stock Income Statement
NASDAQ:LIPO - Nasdaq - US53630L2097 - Common Stock - Currency: USD
| TTM (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 483.50K | 449.60K | 184.20K | 259.40K | 961.70K | |||
| Operating Expenses | 4.84M | 5.20M | 2.77M | 2.18M | 1.02M | |||
| Research and Development | 3.01M | 3.04M | 2.55M | 1.46M | 976.00K | |||
| Selling, General, and Administrative Expenses | 1.84M | 2.16M | 226.20K | 718.40K | 42.60K | |||
| Operating Income | -4.36M | -4.75M | -2.59M | -1.92M | -56.90K | |||
| Interest Income/Expense | 95.30K | 127.00K | -7.90K | -6.70K | -4.80K | |||
| Other Income/Expense | N/A | 0.00 | -100.00 | 57.10K | 0.00 | |||
| Income Before Taxes | -4.26M | -4.62M | -2.60M | -1.87M | -61.70K | |||
| Income Tax | N/A | N/A | 0.00 | 0.00 | 0.00 | |||
| Net Income | -4.26M | -4.62M | -2.60M | -1.87M | -61.70K | |||
| EBITDA | -4.36M | -4.74M | N/A | N/A | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -4.40 | -6.16 | -5.12 | -2.60 | -0.01 | |||
| Statistics | ||||||||
| Profit Margin | -881.80% | -1027.36% | -1410.26% | -719.16% | -6.42% | |||
| Operating Profit Margin | -901.51% | -1055.60% | -1405.92% | -738.55% | -5.92% | |||
All data in USD